Surgery
CHIMERA: A Phase II Study of Neoadjuvant Pembrolizumab in Combination With Cisplatin or Carboplatin and Pemetrexed Followed by Surgery and Adjuvant Pembrolizumab in Resectable Pleural Mesothelioma
Clinical Lung Cancer 2026 July [Link] Giulia Pasello, Daniela Scattolin, Eleonora Faccioli, Paolo Andrea Zucali, Giuseppe Marulli, Federica Grosso, Giovanni Luca Ceresoli, Marcello Tiseo, Alessandra Bearz, Fabiana Letizia Cecere, Luana Calabrò, Francesco Callegarin, Paola Del Bianco, Gian Luca De Salvo, Federica Pezzuto, Fiorella Calabrese, Valentina Guarneri, Andrea Dell’Amore, Federico Rea Abstract Pleural mesothelioma (PM) is…
Read MoreA single-center experience in parenchyma-sparing surgical treatment of malignant pleural mesothelioma
Updates in Surgery 2026 June 1 [Link] Giuseppe Mangiameli, Debora Brascia, Emanuela Re Cecconi, Veronica Maria Giudici, Edoardo Bottoni, Alessandro Crepaldi, Umberto Cariboni, Alberto Testori, Paolo Zucali, Matteo Perrino, Nadia Cordua, Armando Santoro, Marco Alloisio, Giuseppe Marulli Abstract The role of surgery in malignant pleural mesothelioma (MPM) remains controversial, particularly after the negative results of…
Read MoreFeasibility and Outcomes of Cytoreductive Surgery and Hyperthermic Intrathoracic Chemoperfusion for Pleural Mesothelioma
The Annals of Thoracic Surgery 2026 May 28 [Link] Yota Suzuki, Inderpal S Sarkaria, Edra Ha, Ian G Christie, Olugbenga T Okusanya, Omar Awais, Evan T Alicuben, Ryan M Levy, James D Luketich, Neil A Christie Abstract Background: The management of pleural mesothelioma requires a multidisciplinary approach, and hyperthermic intrathoracic chemoperfusion (HITHOC) after surgical cytoreduction…
Read MoreFASN for diffuse malignant peritoneal mesothelioma: a prognostic biomarker after CRS+HIPEC and a therapeutic target
Journal of Translational Medicine 2026 May 21 [Link] Valentina Doldi, Chiara Maura Ciniselli, Claudia Aurelio, Enrica Favini, Silvio Marco Veronese, Fabio Bozzi, Shigeki Kusamura, Dario Baratti, Silvia Martini, Paolo Verderio, Marcello Deraco, Marco Folini, Paolo Gandellini, Sandro Pasquali, Nadia Zaffaroni Abstract Background: Diffuse malignant peritoneal mesothelioma (DMPM) is a rare and aggressive malignancy with limited…
Read MoreQuantitative MRI-Based T Category in Pleural Mesothelioma: Analysis of a Large Real-World Cohort
Academic Radiology 2026 May 15 [Link] Ritu R Gill, William G Richards, Emanuele Mazzola, Beow Y Yeap, Raphael Bueno Abstract Rationale and objectives: Accurate clinical staging in pleural mesothelioma (PM) is limited by the subjectivity of conventional imaging assessment, which introduces inter- and intraobserver variability. Tumor volume, pleural thickness and diaphragmatic thickness measurements individually prognostic…
Read MorePIPAC for Malignant Peritoneal Mesothelioma: Current Insights and Future Directions
Digestive Surgery 2026 May 12 [Link] Arianna Castagna, Aphrodite Fotiadou, Ali Ramouz, Preslava Gesheva, Niall Brindl, Wiebke Solass, Andreas Brandl Abstract Malignant peritoneal mesothelioma (MPM) is a rare and aggressive tumour with poor prognosis, often diagnosed late due to nonspecific symptoms. Current standard treatment involves systemic chemotherapy and cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy…
Read MoreImpact of a national mesothelioma network on outcomes including survival
Thorax 2026 May 8 [Link] Matthew Tate, Joshua Joseph Roche, Selina Tsim, Neil McGlinchey, Katie Ferguson, Phil Reid, Philip Short, Mahendran Chetty, Clinton Ali, Noelle O’Rourke, Carol MacGregor, Carolyn MacRae, Laura McNaughton, Rebecca Bloomfield, Tracey Petrie, Susan Smyth, Jennifer Latham, Lynne Hunter, Rocco Bilancia, Alan Kirk, Craig Dick, Fiona Roberts, Elaine MacDuff, Jill Slavin, Hemamalini…
Read MoreReal-world outcomes of multimodal treatment for pleural mesothelioma: A retrospective study in a high-volume integrated regional center
JTCVS Open 2026 January 30 [Link] Alison S Baskin, Keza Levine, Yun-Yi Hung, Elaine Liang, Kian C Banks, J Marie Suga, Jeffrey B Velotta Abstract Objective: To evaluate overall survival (OS) associated with multimodal treatment regimens, including pleurectomy/decortication (PD) and systemic therapy, in patients with clinical stage I-II epithelioid pleural mesothelioma (PM). Methods: We identified…
Read MoreImmunotherapy resistance and strategies in malignant pleural mesothelioma
Cancer Drug Resistance 2026 March 26 [Link] Wanyi Xia, Yulong Zhang, Juanzhi Zhao, Xiaoli Tan, Shaolong Ju, Wei Zou, Chaoqun Chen, Chunwei Li, Yanghua Xu, Yingming Peng, Shengqiao Li Abstract Malignant pleural mesothelioma (MPM) remains one of the most aggressive thoracic malignancies, characterized by profound resistance to conventional modalities such as surgery, chemotherapy, and radiotherapy,…
Read MoreThe Society of Thoracic Surgeons 2026 Expert Consensus on the Multimodal Treatment of Pleural Mesothelioma
The Annals of Thoracic Surgery 2026 July [Link] Jeffrey B Velotta, Anja C Roden, Jonathan Rice, Charles B Simone, Bansari Upadhyay, Pallavi Sood, Daniel L Miller, R Taylor Ripley, Andrea Wolf, Bryan M Burt, Samuel S Kim, Isabelle Opitz, Hedy L Kindler, Harvey I Pass, J W Awori Hayanga, Valerie Rusch, Raphael Bueno Abstract Background:…
Read More
Skip to content